Advertisement

Periostin pp 145-159 | Cite as

Roles of Periostin in Asthma

  • Hisako MatsumotoEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1132)

Abstract

Periostin is a matricellular protein that is deeply involved in type-2/eosinophilic airway inflammation and remodeling in asthma. While its expression in airway epithelial cells is correlated with the thickness of airway basement membrane, more importantly, periostin can be detected stably in blood with little variability, reflecting airway type-2 inflammation and remodeling. As for a result, serum periostin can serve as a valuable marker to identify patients with type-2 severe asthma who are insensitive to inhaled corticosteroids, and consequently have the excess decline of pulmonary function with asthma exacerbations. Serum periostin may significantly help to improve management of patients with severe asthma.

Keywords

Serum periostin Biomarker Severe asthma Type-2 inflammation Airway remodeling Airflow limitation Eosinophilic chronic rhinosinusitis IL4RA 

References

  1. 1.
    Chung KF, Wenzel SE, Brozek JL et al (2014) International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43:343–373CrossRefGoogle Scholar
  2. 2.
    Matsumoto H (2014) Serum periostin: a novel biomarker for asthma management. Allergol Int 63:153–160CrossRefGoogle Scholar
  3. 3.
    Izuhara K, Matsumoto H, Ohta S, Ono J, Arima K, Ogawa M (2015) Recent developments regarding periostin in bronchial asthma. Allergol Int 64(Suppl):S3–S10CrossRefGoogle Scholar
  4. 4.
    Izuhara K, Conway SJ, Moore BB et al (2016) Roles of periostin in respiratory disorders. Am J Respir Crit Care Med 193:949–956CrossRefGoogle Scholar
  5. 5.
    Yuyama N, Davies DE, Akaiwa M et al (2002) Analysis of novel disease-related genes in bronchial asthma. Cytokine 19:287–296CrossRefGoogle Scholar
  6. 6.
    Woodruff PG, Boushey HA, Dolganov GM et al (2007) Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 104:15858–15863CrossRefGoogle Scholar
  7. 7.
    Lopez-Guisa JM, Powers C, File D, Cochrane E, Jimenez N, Debley JS (2012) Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol 129:990–997. e996CrossRefGoogle Scholar
  8. 8.
    Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV (2014) Measures of gene expression in sputum cells can identify T2-high and T2-low subtypes of asthma. J Allergy Clin Immunol 133:388–394CrossRefGoogle Scholar
  9. 9.
    Takayama G, Arima K, Kanaji T et al (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118:98–104CrossRefGoogle Scholar
  10. 10.
    Komiya K, Ohta S, Arima K et al (2017) Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. Respir Res 18:37CrossRefGoogle Scholar
  11. 11.
    Makita K, Mikami Y, Matsuzaki H et al (2018) Mechanism of periostin production in human bronchial smooth muscle cells. Int Arch Allergy Immunol 175:26–35CrossRefGoogle Scholar
  12. 12.
    Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A (2013) Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy 68:1467–1470CrossRefGoogle Scholar
  13. 13.
    Li W, Gao P, Zhi Y et al (2015) Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res 16:57CrossRefGoogle Scholar
  14. 14.
    Sidhu SS, Yuan S, Innes AL et al (2010) Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A 107:14170–14175CrossRefGoogle Scholar
  15. 15.
    Kanemitsu Y, Ito I, Niimi A et al (2014) Osteopontin and periostin associate with a 20-year decline of pulmonary function in asthmatics. Am J Respir Crit Care Med 190:472–474CrossRefGoogle Scholar
  16. 16.
    Woodruff PG, Modrek B, Choy DF et al (2009) T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180:388–395CrossRefGoogle Scholar
  17. 17.
    Sehra S, Yao W, Nguyen ET et al (2011) Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 186:4959–4966CrossRefGoogle Scholar
  18. 18.
    Gordon ED, Sidhu SS, Wang ZE et al (2012) A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 42:144–155CrossRefGoogle Scholar
  19. 19.
    Blanchard C, Mingler MK, McBride M et al (2008) Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 1:289–296CrossRefGoogle Scholar
  20. 20.
    Bentley JK, Chen Q, Hong JY et al (2014) Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol 134:1433–1442CrossRefGoogle Scholar
  21. 21.
    Johansson MW, Annis DS, Mosher DF (2013) Alpha (M)beta(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol 48:503–510CrossRefGoogle Scholar
  22. 22.
    Johansson MW, Khanna M, Bortnov V, Annis DS, Nguyen CL, Mosher DF (2017) IL-5-stimulated eosinophils adherent to periostin undergo stereotypic morphological changes and ADAM8-dependent migration. Clin Exp Allergy 47:1263–1274CrossRefGoogle Scholar
  23. 23.
    Noguchi T, Nakagome K, Kobayashi T et al (2016) Periostin upregulates the effector functions of eosinophils. J Allergy Clin Immunol 138:1449–1452 e1445CrossRefGoogle Scholar
  24. 24.
    Kanemitsu Y, Matsumoto H, Izuhara K et al (2013) Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 132:305–312. e303CrossRefGoogle Scholar
  25. 25.
    Matsusaka M, Kabata H, Fukunaga K et al (2015) Phenotype of asthma related with high serum periostin levels. Allergol Int 64:175–180CrossRefGoogle Scholar
  26. 26.
    James A, Janson C, Malinovschi A et al (2017) Serum periostin relates to type-2 inflammation and lung function in asthma: data from the large population-based cohort Swedish GA(2)LEN. Allergy 72:1753–1760CrossRefGoogle Scholar
  27. 27.
    Anderson HM, Lemanske RF, Jr., Arron JR, et al., Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development. J Allergy Clin Immunol 2017; 139: 790–796CrossRefGoogle Scholar
  28. 28.
    Inoue T, Akashi K, Watanabe M et al (2016) Periostin as a biomarker for the diagnosis of pediatric asthma. Pediatr Allergy Immunol 27:521–526CrossRefGoogle Scholar
  29. 29.
    Song JS, You JS, Jeong SI et al (2015) Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma. Allergy 70:674–681CrossRefGoogle Scholar
  30. 30.
    Arron JR, Izuhara K (2015) Asthma biomarkers: what constitutes a ‘gold standard’? Thorax 70:105–107CrossRefGoogle Scholar
  31. 31.
    Okamoto M, Hoshino T, Kitasato Y et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37:1119–1127CrossRefGoogle Scholar
  32. 32.
    Palme S, Christenson RH, Jortani SA et al (2017) Multicenter evaluation of analytical characteristics of the Elecsys((R)) periostin immunoassay. Clin Biochem 50:139–144CrossRefGoogle Scholar
  33. 33.
    Corren J, Lemanske RF, Hanania NA et al (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365:1088–1098CrossRefGoogle Scholar
  34. 34.
    Jia G, Erickson RW, Choy DF et al (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130:647–654 e610CrossRefGoogle Scholar
  35. 35.
    Semprini R, Caswell-Smith R, Fingleton J et al (2017) Longitudinal variation of serum periostin levels in adults with stable asthma. J Allergy Clin Immunol 139:1687–1688. e1689CrossRefGoogle Scholar
  36. 36.
    Caswell-Smith R, Cripps T, Charles T et al (2017) Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma. Allergy, Asthma Clin Immunol 13:8CrossRefGoogle Scholar
  37. 37.
    Kuo CS, Pavlidis S, Loza M et al (2017) T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J 49:1602135CrossRefGoogle Scholar
  38. 38.
    Fingleton J, Braithwaite I, Travers J et al (2016) Serum periostin in obstructive airways disease. Eur Respir J 47:1383–1391CrossRefGoogle Scholar
  39. 39.
    Asano T, Kanemitsu Y, Takemura M et al (2017) Serum periostin as a biomarker for comorbid chronic rhinosinusitis in patients with asthma. Ann Am Thorac Soc 14:667–675CrossRefGoogle Scholar
  40. 40.
    Takahashi K, Meguro K, Kawashima H et al (2018) Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma 12:1–8Google Scholar
  41. 41.
    Hoshino M, Ohtawa J, Akitsu K (2016) Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma. Respirology 21:297–303CrossRefGoogle Scholar
  42. 42.
    Kimura H, Konno S, Makita H et al (2018) Serum periostin is associated with body mass index and allergic rhinitis in healthy and asthmatic subjects. Allergol Int 67:357–363CrossRefGoogle Scholar
  43. 43.
    Bumbacea D, Campbell D, Nguyen L et al (2004) Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24:122–128CrossRefGoogle Scholar
  44. 44.
    Nagasaki T, Matsumoto H, Kanemitsu Y et al (2014) Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 133:1474–1477. e1472CrossRefGoogle Scholar
  45. 45.
    Haldar P, Pavord ID, Shaw DE et al (2008) Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178:218–224CrossRefGoogle Scholar
  46. 46.
    Amelink M, de Nijs SB, de Groot JC et al (2013) Three phenotypes of adult-onset asthma. Allergy 68:674–680CrossRefGoogle Scholar
  47. 47.
    Nagasaki T, Matsumoto H, Kanemitsu Y et al (2014) Using exhaled nitric oxide and serum periostin as a composite marker to identify severe/steroid-insensitive asthma. Am J Respir Crit Care Med 190:1449–1452CrossRefGoogle Scholar
  48. 48.
    Dweik RA, Sorkness RL, Wenzel S et al (2010) Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 181:1033–1041CrossRefGoogle Scholar
  49. 49.
    Mansur AH, Srivastava S, Sahal A (2018) Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med 143:31–38CrossRefGoogle Scholar
  50. 50.
    Nagasaki T, Matsumoto H, Izuhara K (2017) Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma. Allergol Int 66:404–410CrossRefGoogle Scholar
  51. 51.
    Hinks TS, Brown T, Lau LC et al (2016) Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol 138:61–75CrossRefGoogle Scholar
  52. 52.
    Sunadome H, Matsumoto H, Petrova G et al (2017) IL4Ralpha and ADAM33 as genetic markers in asthma exacerbations and type-2 inflammatory endotype. Clin Exp Allergy 47:998–1006CrossRefGoogle Scholar
  53. 53.
    Slager RE, Otulana BA, Hawkins GA et al (2012) IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 130:516–522. e514CrossRefGoogle Scholar
  54. 54.
    Ishida A, Ohta N, Suzuki Y et al (2012) Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 61:589–595CrossRefGoogle Scholar
  55. 55.
    Kimura H, Konno S, Nakamaru Y et al (2017) Sinus computed tomographic findings in adult smokers and nonsmokers with asthma. Analysis of clinical indices and biomarkers. Ann Am Thorac Soc 14:332–341CrossRefGoogle Scholar
  56. 56.
    Kim MA, Izuhara K, Ohta S et al (2014) Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 113:314–320CrossRefGoogle Scholar
  57. 57.
    Tajiri T, Matsumoto H, Hiraumi H et al (2013) Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 110:387–388CrossRefGoogle Scholar
  58. 58.
    Mertens TCJ, van der Does AM, Kistemaker LE, Ninaber DK, Taube C, Hiemstra PS (2017) Cigarette smoke differentially affects IL-13-induced gene expression in human airway epithelial cells. Phys Rep 5:e13347CrossRefGoogle Scholar
  59. 59.
    Thomson NC, Chaudhuri R, Spears M, Haughney J, McSharry C (2015) Serum periostin in smokers and never smokers with asthma. Respir Med 109:708–715CrossRefGoogle Scholar
  60. 60.
    Shirai T, Hirai K, Gon Y, et al (2018) Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol Pract. E-pub ahead of printGoogle Scholar
  61. 61.
    Carpaij OA, Muntinghe FOW, Wagenaar MB et al (2018) Serum periostin does not reflect type 2-driven inflammation in COPD. Respir Res 19:112CrossRefGoogle Scholar
  62. 62.
    Konstantelou E, Papaioannou AI, Loukides S et al (2017) Serum periostin in patients hospitalized for COPD exacerbations. Cytokine 93:51–56CrossRefGoogle Scholar
  63. 63.
    Caswell-Smith R, Hosking A, Cripps T et al (2016) Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease. Clin Exp Allergy 46:1303–1314CrossRefGoogle Scholar
  64. 64.
    James A, Ono J, Kupczyk M, Ohta S, Izuhara K, Dahlen SEK (2013) Controlled oral steroid intervention decreases serum periostin levels in asthmatic patients. Am J Respir Crit Care Med (Abstract) 187:A6005Google Scholar
  65. 65.
    Semprini R, Shortt N, Ebmeier S, et al (2018) Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. Thorax. E-pub ahead of printGoogle Scholar
  66. 66.
    Kato G, Takahashi K, Izuhara K, Komiya K, Kimura S, Hayashi S (2013) Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights 8:97–105CrossRefGoogle Scholar
  67. 67.
    Izuhara Y, Matsumoto H, Kanemitsu Y et al (2014) GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy 69:668–673CrossRefGoogle Scholar
  68. 68.
    Hanania NA, Wenzel S, Rosen K et al (2013) Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:804–811CrossRefGoogle Scholar
  69. 69.
    Tajiri T, Matsumoto H, Gon Y et al (2016) Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy 71:1472–1479CrossRefGoogle Scholar
  70. 70.
    Caminati M, Gatti D, Dama A, Lorenzetti L, Senna G (2017) Serum periostin during omalizumab therapy in asthma: a tool for patient selection and treatment evaluation. Ann Allergy Asthma Immunol 119:460–462CrossRefGoogle Scholar
  71. 71.
    Hanania NA, Korenblat P, Chapman KR et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781–796CrossRefGoogle Scholar
  72. 72.
    Liu Y, Zhang S, Chen R et al (2018) Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma. Allergy Asthma Proc 39:332–337CrossRefGoogle Scholar
  73. 73.
    Castro M, Corren J, Pavord ID et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496CrossRefGoogle Scholar
  74. 74.
    Simpson JL, Yang IA, Upham JW et al (2016) Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med 16:67CrossRefGoogle Scholar
  75. 75.
    Carpagnano GE, Scioscia G, Lacedonia D et al (2018) Looking for airways periostin in severe asthma: could it be useful for clustering type 2 endotype? Chest 154:1083–1090CrossRefGoogle Scholar
  76. 76.
    Wardzynska A, Makowska JS, Pawelczyk M, Piechota-Polanczyk A, Kurowski M, Kowalski ML (2017) Periostin in exhaled breath condensate and in serum of asthmatic patients: relationship to upper and lower airway disease. Allergy, Asthma Immunol Res 9:126–132CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Respiratory MedicineKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations